<DOC>
	<DOCNO>NCT00654875</DOCNO>
	<brief_summary>This study compare safety efficacy daily dose aliskiren twice daily dose aliskiren patient moderate hypertension</brief_summary>
	<brief_title>Efficacy Safety Once Daily Dosing Aliskiren ( 300 mg ( qd ) Once Day ) Twice Daily Dosing Aliskiren ( 150 mg ( Bid ) Twice Day ) Treating Moderate Hypertension .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Have diagnosis uncomplicated essential hypertension ; newly diagnose receive antihypertension medication within 4 week visit 1 must office cuff mean sit Diastolic Blood pressure ( msDBP ) &gt; 100 mmHg &lt; 110 mmHg visit 1 . If patient receive antihypertensive treatment , must cuff msDBP &gt; 95 mmHg &lt; 110 mmHg visit 1 Prior randomization , patient must office cuff msDBP &gt; or= 100 mmHg &lt; = 110 mmHg . Participation another aliskiren trial previous treatment aliskiren last 6 month qualify randomize enrolled active drug treatment period Pregnant nursing woman Women child bear potential unwilling use protocol specific contraceptive method Office cuff blood pressure msDBP ≥ 112 mmHg and/or mean sit Systolic Blood Pressure ( msSBP ) ≥ 200 mmHg ) . Secondary form hypertension History heart failure New York Heart Association ( NYHA Class II , III IV ) Previous history hypertensive encephalopathy stroke , transient ischemic attack ( TIA ) , heart attack , coronary bypass surgery percutaneous coronary intervention ( PCI ) Elevated Serum potassium ( &gt; = 5.3 mEq/L ( mmol/L ) Visit 1 Type 1 Type 2 diabetes mellitus well control Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Essential Hypertension</keyword>
</DOC>